AFF1 and acute lymphoblastic leukemia: In the subsequent protocol ALL-BFM 95, criteria for the allocation to HR were: (1) Ph+ ALL or the translocation KMT2A-AFF1, the latter with a 6-year event-free survival (EFS) in study ALL-BFM 90 of 35%, (18) (2) PPR, and (3) IF.